<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nano Today</journal-id><journal-id journal-id-type="iso-abbrev">Nano Today</journal-id><journal-title-group><journal-title>Nano Today</journal-title></journal-title-group><issn pub-type="ppub">1748-0132</issn><issn pub-type="epub">1878-044X</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7498411</article-id><article-id pub-id-type="publisher-id">S1748-0132(20)30145-6</article-id><article-id pub-id-type="doi">10.1016/j.nantod.2020.100976</article-id><article-id pub-id-type="publisher-id">100976</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antiviral nanoagents: More attention and effort needed?</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Chen</surname><given-names>Yongjiu</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Ma</surname><given-names>Juan</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Xu</surname><given-names>Ming</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Liu</surname><given-names>Sijin</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0015" ref-type="aff">c</xref></contrib><aff id="aff0005"><label>a</label>State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China</aff><aff id="aff0010"><label>b</label>School of Environment, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China</aff><aff id="aff0015"><label>c</label>University of Chinese Academy of Sciences, Beijing 100049, China</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding authors at: State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.</corresp></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>9</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>12</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2020</year></pub-date><volume>35</volume><fpage>100976</fpage><lpage>100976</lpage><history><date date-type="received"><day>23</day><month>2</month><year>2020</year></date><date date-type="rev-recd"><day>28</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="graphical" id="abs0005"><title>Graphical abstract</title><fig id="fig0015" position="anchor"><graphic xlink:href="fx1_lrg"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0010"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">Engineered nanomaterials have emerging as a tool for the development of next-generation antiviral agents.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">Antiviral strategies using nanoagents mainly include virus or host cell surface receptor interactions, antiviral agents delivery, and nanovaccines.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">Future antiviral therapy would require safe, efficient, and broad-spectrum nanoagents.</p></list-item></list></p></abstract><abstract id="abs0015"><p>The recent COVID-19 outbreak has increasingly engaged researchers in the search for effective antiviral drugs as well as therapeutic treatment options. The shortcomings of existing antiviral agents such as narrow spectrum and low bioavailability, can be overcome through the use of engineered nanomaterials, which, therefore, are considered as a significant next-generation therapeutic option. Thus, the development of novel antiviral nanoagents will certainly help address several future challenges and knowledge gaps.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Engineered nanomaterials</kwd><kwd>Antivirus</kwd><kwd>Nanoagents</kwd><kwd>Therapeutics</kwd><kwd>Mechanism</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>Introduction</title><p id="par0020">The novel coronavirus (COVID-19) outbreak has turned into a global pandemic, causing 810,492 deaths and 23,518,343 infected cases in 216 countries, areas, or territories as of August 25, 2020 [<xref rid="bib0005" ref-type="bibr">1</xref>], which is an irreparable loss. Unfortunately, despite considerable advancements in the field of antiviral drug discovery over the past years [<xref rid="bib0010" ref-type="bibr">2</xref>], there is still no approved drug or vaccine that can treat this disease [<xref rid="bib0015" ref-type="bibr">3</xref>]. Likewise, there are over 200 other infectious diseases [<xref rid="bib0010" ref-type="bibr">2</xref>]. In the last two decades, there have been a number of pathogenic viruses that have caused public health emergencies and socioeconomic losses (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>
a). For instance, the severe acute respiratory syndrome (SARS) outbreak in 2003 induced 774 deaths and 8096 infection cases [<xref rid="bib0020" ref-type="bibr">4</xref>], and its economic cost was estimated to be over $US 40 billion [<xref rid="bib0025" ref-type="bibr">5</xref>]. Similarly, approximately 37.9 million people worldwide suffered from the human immunodeficiency virus (HIV) around the end of 2018 [<xref rid="bib0030" ref-type="bibr">6</xref>], leading to an increasing healthcare burden in low-income countries.<fig id="fig0005"><label>Fig. 1</label><caption><p>(a) Major global virus epidemics in the last two decades.</p><p>HIV: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/hiv/mediacentre/events/en/" id="intr0005">https://www.who.int/hiv/mediacentre/events/en/</ext-link>.</p><p>SARS: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/" id="intr0010">https://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/</ext-link>.</p><p>Hemagglutinin type1 neuraminidase type 1 (H1N1): <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/2009_12_30/en/" id="intr0015">https://www.who.int/csr/don/2009_12_30/en/</ext-link>.</p><p>Middle East respiratory syndrome (MERS): <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intr0020">https://www.who.int/emergencies/mers-cov/en/</ext-link>.</p><p>Zika virus (ZIKV): <ext-link ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/zika-virus" id="intr0025">https://www.who.int/en/news-room/fact-sheets/detail/zika-virus</ext-link></p><p>HCV: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-c" id="intr0030">https://www.who.int/news-room/fact-sheets/detail/hepatitis-c</ext-link>.</p><p>Ebola: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/ebola/en/" id="intr0035">https://www.who.int/csr/disease/ebola/en/</ext-link>.</p><p>COVID-19: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019" id="intr0040">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></p><p>(b) Published papers on antibacterial, anticancer, and antiviral studies based on nanomaterials. The data were collected from the Web of Science (<ext-link ext-link-type="uri" xlink:href="http://www.webofknowledge.com" id="intr0045">http://www.webofknowledge.com</ext-link>).</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="par0025">Generally, small-molecule drugs, vaccines, monoclonal antibodies, peptides, interferon, and oligonucleotide-based therapies can be used to combat viral infections such as the application of a SARS vaccine or combinatorial antiretroviral therapy (cART) in the treatment of HIV [<xref rid="bib0035" ref-type="bibr">7</xref>,<xref rid="bib0040" ref-type="bibr">8</xref>]. Nevertheless, up to 2016, only 90 antiviral drugs had been approved for the treatment of 9 types of human transmissible diseases, namely HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), herpesvirus, influenza virus, human cytomegalovirus, varicella-zoster virus, respiratory syncytial virus (RSV), and human papilloma virus (HPV) [<xref rid="bib0010" ref-type="bibr">2</xref>]. Although developments of new antiviral drugs, vaccines, and antibodies are powerful prevention and treatment strategies for viral infections, most of these selectively target a single virus [<xref rid="bib0045" ref-type="bibr">9</xref>]. Moreover, viral mutation, virus-induced secondary infections, side effects from drugs and vaccines, and long development cycles bring many uncertainties and pose challenges to the search for new antiviral drugs. Hence, there is an urgent need to realize more effective therapeutic strategies to combat viral emergence.</p></sec><sec id="sec0010"><title>Nanomaterials present new opportunities for antiviral drug development</title><p id="par0030">Engineered nanomaterials (ENMs) offer many therapeutic advantages over traditional drugs, such as higher efficiency of drug delivery to lesions, more broad-spectrum drug activity, fewer side effects on the human body, easily tunable physicochemical properties, lower cost and higher throughput synthesis, <italic>etc.</italic> These superior properties of ENMs could be considered as an emerging solution to the problems faced during novel drug development. Hence, ENMs have been intensively investigated for their applications in next-generation therapeutics, such as anticancer and antibacterial treatments. However, antiviral applications of ENMs are still in their infancy (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>b). Reportedly (<xref rid="tbl0005" ref-type="table">Table 1</xref>
), antiviral nanoagents can be roughly classified into three strategies, namely virus or host cell surface receptor interactions, antiviral agent delivery, and nanovaccines (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>
).<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Representative antiviral nanoagents in published papers.</p></caption><alt-text id="at0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">ENMs</th><th align="left">Size</th><th align="left">Surface modification / antiviral agent</th><th align="left">Virus<xref rid="tblfn0005" ref-type="table-fn">a</xref></th><th align="left">Study</th><th colspan="2" align="left">Mechanism</th><th align="left">Ref.</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="2">Ag NPs</td><td align="left">16 nm</td><td align="left">Polyvinylpyrrolidone / bovine serum albumin</td><td align="left">HIV-1</td><td align="left"><italic>In vitro</italic></td><td align="left" valign="middle" rowspan="4">Virus or host cell surface receptor interactions</td><td align="left">Binding to gp120 glycoprotein knobs on HIV-1 surface.</td><td align="left">[<xref rid="bib0060" ref-type="bibr">12</xref>]</td></tr><tr><td align="left">50 nm</td><td align="left"/><td align="left">HBV</td><td align="left"><italic>In vitro</italic></td><td align="left">Impeding the transcription of viral RNA by directly binding to HBV DNA.</td><td align="left">[<xref rid="bib0070" ref-type="bibr">14</xref>]</td></tr><tr><td align="left">GO</td><td align="left"/><td align="left"/><td align="left">HSV-1</td><td align="left"><italic>In vitro</italic></td><td align="left">Mimicking the cell surface receptor heparan sulfate to inhibit HSV binding to host cells.</td><td align="left">[<xref rid="bib0080" ref-type="bibr">16</xref>]</td></tr><tr><td align="left">Au NPs</td><td align="left">2.3 nm</td><td align="left">Ligands containing undecane sulfonic acid</td><td align="left">HSV, HPV, RSV, DENV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left">Au NPs coated with undecane sulfonic acid mimicking the heparin sulfate proteoglycans to prevent the virus&#x02013;cell interaction.</td><td align="left">[<xref rid="bib0090" ref-type="bibr">18</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="2">PLGA NPs</td><td align="left">395 nm</td><td align="left">Acyclovir</td><td align="left">HSV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left" valign="middle" rowspan="4">Antiviral agent delivery</td><td align="left">PLGA NPs loaded with acyclovir for oral delivery.</td><td align="left">[<xref rid="bib0100" ref-type="bibr">20</xref>]</td></tr><tr><td align="left">180 nm</td><td align="left">3D8 scFv antibody</td><td align="left">VSV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left">Cytoplasmic delivery of a monoclonal antibody with nucleic acid-hydrolyzing activity.</td><td align="left">[<xref rid="bib0170" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="2">Liposome</td><td align="left">150 nm</td><td align="left">Suramin</td><td align="left">NV</td><td align="left"><italic>In vitro</italic></td><td align="left">Delivery the suramin-loaded liposome to inhibit NV polymerases.</td><td align="left">[<xref rid="bib0110" ref-type="bibr">22</xref>]</td></tr><tr><td align="left">124 nm</td><td align="left">Stearylamine</td><td align="left">BV, HSV-1</td><td align="left"><italic>In intro</italic></td><td align="left">Cationic liposomes with incorporated stearylamine inhibit viral infectivity.</td><td align="left">[<xref rid="bib0175" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="4">Au NPs</td><td align="left">5, 50, 100 nm</td><td align="left">Thiol cysteamine</td><td align="left">HCV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left" valign="middle" rowspan="4">Nanovaccines</td><td align="left">DNA segment specific to HCV core gene conjugated on the AuNPs to simulate the immune response.</td><td align="left">[<xref rid="bib0135" ref-type="bibr">27</xref>]</td></tr><tr><td align="left">2 2, 5, 8, 12, 17, 37, 50 nm</td><td align="left">FMDV peptide</td><td align="left">FMDV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left">C-terminus of the FMDV peptide conjugated on AuNPs to induce the magnitude of the immune response.</td><td align="left">[<xref rid="bib0180" ref-type="bibr">36</xref>]</td></tr><tr><td align="left">20,40 nm</td><td align="left">WNV envelope E protein</td><td align="left">WNV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left">WNV envelope E protein coated AuNPs enhance the immune response.</td><td align="left">[<xref rid="bib0185" ref-type="bibr">37</xref>]</td></tr><tr><td align="left">20, 40, 80 nm</td><td align="left">ED III protein</td><td align="left">DENV</td><td align="left"><italic>In vivo</italic>, <italic>in vitro</italic></td><td align="left">Serotype 2 of DENV as dengue subunit to functionalize Au NPs to induce a high level of antibody to neutralizing DENV.</td><td align="left">[<xref rid="bib0190" ref-type="bibr">38</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tblfn0005"><label>a</label><p id="npar0005">DENV: dengue virus; VSV: vesicular stomatitis virus; BV: baculovirus; ED III: domain III of envelope glycoprotein derived from serotype 2 of dengue virus. RANTES: regulated upon activation, normal T expressed and secreted.</p></fn></table-wrap-foot></table-wrap><fig id="fig0010"><label>Fig. 2</label><caption><p>Three antiviral strategies for nanoagents: (a) virus or host cell surface receptor interactions, (b) antiviral agent delivery, and (c) nanovaccines. Red cross denotes the targets of ENMs against the virus&#x02212;cell interactions.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><sec id="sec0015"><title>Virus or host cell surface receptor interactions</title><p id="par0035">A virus is an extremely small particle with an outer protein shell called a capsid and an inner core of nucleic acids (either RNA or DNA). For self-replication, the virus has to invade host cells through binding itself to specific &#x0201c;cell surface receptor molecules&#x0201d; (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>a), such as the angiotensin-converting enzyme 2 (ACE2) receptor for COVID-19 [<xref rid="bib0050" ref-type="bibr">10</xref>]. Antiviral nanoagents can be used to disrupt the viral replication cycle. As shown in <xref rid="tbl0005" ref-type="table">Table 1</xref>, multifarious nanoagents have been widely investigated for their antiviral activities, such as metallic (<italic>e.g.</italic>, silver), metal oxide (<italic>e.g.,</italic> titanium dioxide), and carbonaceous (<italic>e.g.</italic>, graphene oxide (GO)) nanomaterials. The controllable physicochemical properties (<italic>e.g.</italic>, size, shape, and surface) of ENMs facilitate their direct interactions with viral particles or host cell surface receptors to inhibit virus-cell interactions [<xref rid="bib0055" ref-type="bibr">11</xref>]. For instance, silver nanoparticles (Ag NPs) can directly interact with virus envelope proteins [<xref rid="bib0060" ref-type="bibr">12</xref>,<xref rid="bib0065" ref-type="bibr">13</xref>], and nucleic acids [<xref rid="bib0070" ref-type="bibr">14</xref>]. Furthermore, our recent study revealed that AgNPs could block the primary infection of Kaposi&#x02019;s sarcoma-associated herpesvirus (KSHV) by directly destroying its virion protein [<xref rid="bib0075" ref-type="bibr">15</xref>]. In addition, GO and its derivatives were reported to inhibit virus infections through competitive binding with the cell receptors [<xref rid="bib0080" ref-type="bibr">16</xref>], or inducing conformational damage of the viral protein [<xref rid="bib0085" ref-type="bibr">17</xref>]. Analogously, by mimicking heparan sulfate proteoglycans on the eukaryotic cell surface, viral attachment ligand (VAL)-modified gold nanoparticles (Au NPs) exhibit a broad-spectrum nontoxic antiviral activity [<xref rid="bib0090" ref-type="bibr">18</xref>].</p></sec><sec id="sec0020"><title>Antiviral agent delivery</title><p id="par0040">Many antiviral agents have been approved for clinical use or in preclinical tests based on the basis of disturbing the virus life cycle, which can be used to develop new antiviral approaches in combination with ENMs (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>b). In this way, ENMs can not only function as an ideal vehicle for these agents to improve targeting efficiency, bioavailability and blood circulation, but also reduce side effects [<xref rid="bib0095" ref-type="bibr">19</xref>]. For instance, as an approved antiviral drug, acyclovir can be used to treat herpes simplex virus (HSV) infection through disruption of the viral DNA polymerase function by acting as an analog of deoxyguanosine triphosphate to compete with 2&#x02032;-deoxyaguanosine-5&#x02032;-triphosphate [<xref rid="bib0010" ref-type="bibr">2</xref>]. However, its clinical application is hampered by its short half-life of less than 3&#x0202f;h and low bioavailability (only 10 %&#x02212;20 %) through oral administration [<xref rid="bib0100" ref-type="bibr">20</xref>]. These limitations can be overcome by using poly(lactic acid-co-glycolic acid) (PLGA) as an ideal biodegradable vehicle for drug delivery, which has been approved for clinical application by U.S. Food and Drug Administration. Encapsulation of acyclovir into PLGA-based NPs for oral administration has been demonstrated as an effective way that resulted in a 2.6-fold improvement in its bioavailability [<xref rid="bib0100" ref-type="bibr">20</xref>]. Furthermore, liposomes hold promise as a kind of antiviral drug delivery agent. For instance, although suramin is an active antiretroviral agent that can inhibit HBV, HIV, ZIKV and norovirus (NV) [<xref rid="bib0105" ref-type="bibr">21</xref>], its lipophilicity and high negative charge lead to low membrane permeability and limited cell internalization [<xref rid="bib0110" ref-type="bibr">22</xref>]. However, its encapsulation into cationic liposomal NPs has been reported to result in better inhibition of murine NV infections [<xref rid="bib0110" ref-type="bibr">22</xref>].</p></sec><sec id="sec0025"><title>Nanovaccines</title><p id="par0045">The biological basis for developing nanovaccines is the activation of the host&#x02019;s immune system against viruses through nanoagents (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>c). For this purpose, the dominant antigens of viruses can be used to construct nanovaccines for pathogenic viruses. Thus, ENMs loaded with viral antigens (viral nucleic acids or inactivated proteins) can pre-stimulate the immune system to produce specific virus antibodies that promote antiviral inflammatory responses [<xref rid="bib0115" ref-type="bibr">23</xref>,<xref rid="bib0120" ref-type="bibr">24</xref>]. For instance, Au NPs modified with West Nile virus (WNV) envelope proteins have been demonstrated to stimulate the release of proinflammatory factors (<italic>i.e.</italic>, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), interleuin-6 (IL-6), interleuin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor) to achieve antiviral immune responses [<xref rid="bib0125" ref-type="bibr">25</xref>]. Similarly, the loading of viral DNA or RNA onto ENMs is another effective way of preparing nanovaccines by introducing an eukaryotic expression vector to encode the viral antigen protein into a host cell to provoke the immune system into combating viral infections [<xref rid="bib0130" ref-type="bibr">26</xref>]. Moreover, ENMs can also be used as an auxiliary to overcome the obstacle of inefficient DNA vaccine intake [<xref rid="bib0135" ref-type="bibr">27</xref>]. The coadministration of Au NPs with an anti-HCV DNA vaccine was observed to generate vibrational and dipole-like oscillations, increase the DNA vaccine uptake, and ultimately improve antibody levels and immune response to the HCV infection in immunized mice [<xref rid="bib0135" ref-type="bibr">27</xref>]. Furthermore, nanovaccines based on genetic engineering, bioconjugation, infusion, or mineralization have been successfully applied to treat infections due to HIV-1, Ebola, and foot-and-mouth disease virus (FMDV) [<xref rid="bib0140" ref-type="bibr">28</xref>].</p></sec></sec><sec id="sec0030"><title>Challenges and knowledge gaps</title><p id="par0050">The COVID-19 outbreak has led to increased efforts toward the development of more antiviral nanoagents as a reserve strategy in the fight against viral epidemics. Research thus far has mostly focused only on the development of new drugs and vaccines, or reusing approved antiviral drugs [<xref rid="bib0015" ref-type="bibr">3</xref>], while the absence of antiviral nanoagents during this emergency is conspicuous. Moreover, despite the promising versatility of ENMs in antiviral applications, practical therapeutics are limited in terms of the development of new strategies and improvements in efficacy and safety. The following are a few such limitations:<list list-type="simple" id="lis0010"><list-item id="lsti0020"><label>(i)</label><p id="par0055">Although most reported antiviral nanoagents exhibit outstanding performance in mammalian cell lines or rodents, they may cause adverse or more complicated responses in humans. Hence, before rushing into the clinic, more preclinical tests using promising animal models (<italic>e.g.</italic>, ferrets, macaques, and other primates) that better mimic human disease response must be performed to assess the health risks as well as the antiviral activity of nanoagents. More importantly, massive preclinical tests are prerequisite for the development of nanoagents with better efficacy and broad-spectrum antiviral activity than current approved antiviral drugs.</p></list-item><list-item id="lsti0025"><label>(ii)</label><p id="par0060">Compared to bacteria, virus infections are more complicated, involving faster transmission and a variable incubation period. For instance, although both SARS and COVID-19 belong to the coronavirus family, they exhibit different infectious and pathogenic effects on patients [<xref rid="bib0145" ref-type="bibr">29</xref>]. Therefore, the design of novel antiviral nanoagents for a severe viral pandemic requires not only specific and broad-spectrum activities of antiviral nanoagents, but also a better understanding of the infection mechanisms, especially for viruses exhibiting a high mutation rate and tolerance to approved drugs or vaccine treatments [<xref rid="bib0150" ref-type="bibr">30</xref>].</p></list-item><list-item id="lsti0030"><label>(iii)</label><p id="par0065">The envelope, capsid, and nucleic acids are the primary targets in the design of antiviral nanoagents. However, the interactions between ENMs and these targets remain unclear, which hampers a deeper understanding of the mechanisms that inhibit virus infection. Therefore, the possible interaction mechanisms, including the damage caused by the direct binding of ENMs to viruses, the disturbance of interactions between virus and host cell, or the indirect effects on the activation of innate and adaptive immunity, should be clarified.</p></list-item><list-item id="lsti0035"><label>(iv)</label><p id="par0070">A viral infection involves the following stages: attachment to membrane receptors, penetration into cells, intracellular uncoating, nucleic acid synthesis, and the transfer of progeny virus between cells. Existing databases and bioinformatics should be better used to propose strategies for designing novel antiviral nanoagents that can inhibit the abovementioned processes. Furthermore, the prediction and screening of the interactions between ENMs and viruses during the infection process requires more powerful and high-throughput analytical platforms.</p></list-item><list-item id="lsti0040"><label>(v)</label><p id="par0075">The antiviral nanoagent treatments may also act on the immune system. Therefore, better manipulation of the physicochemical properties (<italic>e.g.</italic>, surface modification) of ENMs is necessary to avoid their side effects, in addition to the well-balanced dose administration. In addition, the reasons for secondary adverse outcomes remain unclear, which can be caused by either ENM-induced nonspecific immune response or virus-incurred inflammation during treatment. Therefore, besides virus infection, the immune activation associated with the type and dosage of the applied ENMs should be considered as well.</p></list-item><list-item id="lsti0045"><label>(vi)</label><p id="par0080">The controllable delivery of antiviral nanoagents to lesions is an important concern during the treatment of diverse viruses. Generally, intravenous administration may be the most commonly used clinical route, especially for treating an infection due to influenza virus. However, for gastrointestinal infections caused by rotavirus or hepatitis virus, oral administration is better, while intranodal administration may be better for treating infections caused by respiratory viruses such as SARS and COVID-19. Therefore, the stability and bioavailability of antiviral nanoagents must be carefully assessed, considering the features of both diverse administration methods and different viruses.</p></list-item><list-item id="lsti0050"><label>(vii)</label><p id="par0085">The rapid increase in the variety of ENMs provides space for healthcare innovations as well as opportunities for the development of novel antiviral agents. However, both the advantages and limitations of ENMs must be well understood to avoid additional risks before practical applications. For example, owing to their high surface-to-volume ratio and modifiable surface properties, two-dimensional ENMs such as GO have been demonstrated as useful tools for anticancer drug delivery [<xref rid="bib0155" ref-type="bibr">31</xref>,<xref rid="bib0160" ref-type="bibr">32</xref>], although their biocompatibility remains a question. Therefore, the possible use of two-dimensional ENMs for antiviral treatments warrants further exploration in the future [<xref rid="bib0165" ref-type="bibr">33</xref>].</p></list-item></list>
</p></sec><sec id="sec0035"><title>Conclusions and perspectives</title><p id="par0090">The development of novel antiviral nanoagents may be a vital and highly desirable precaution against the emergence and recurrence of viral outbreaks. Compared with state-of-the-art approaches such as interfering RNAs, ENMs offer distinct advantages for antiviral therapy, including tunable physicochemical properties, high drug-loading efficacy and bioavailability, feasible incorporation of both hydrophilic and hydrophobic antiviral drugs, and outstanding stability under physiological conditions. Moreover, although diverse ENM-based antiviral strategies have already been proposed based on lab studies, their application in practical therapeutics is still in its infancy. Thus, the current challenges and knowledge gaps in the development of novel antiviral nanoagents, such as the therapeutic efficacy and potential health risks need to be addressed. Nevertheless, future research on antiviral nanoagents and combination therapy using approved antiviral drugs and ENMs is expected to produce promising developments.</p></sec><sec id="sec0040"><title>Funding</title><p id="par0095">This work has been supported by grants from the <funding-source id="gs0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (21922611, 21707161, 21637004, and 21920102007), the <funding-source id="gs0010">Youth Innovation Promotion Association CAS</funding-source> (2019042), the <funding-source id="gs0015"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004826</institution-id><institution>Beijing Natural Science Foundation</institution></institution-wrap></funding-source> (8191002), and the <funding-source id="gs0020">international collaboration key grant from the Chinese Academy of Sciences</funding-source> (121311KYSB20190010).</p></sec><sec id="sec0045"><title>Author contributions</title><p id="par0100">Literature review and initial drafting of the manuscript were performed by Y. C., J. M., and M. X. Critical revisions of the manuscript were performed by M. X. and S. L. Each author has read and approved the final manuscript.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0105">The authors report no declarations of interest.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><mixed-citation publication-type="other" id="oref0005">Coronavirus disease (COVID-2019) situation reports, WHO, <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" id="intr0050">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</ext-link>.</mixed-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group><source>Clin. Microbiol. Rev.</source><volume>29</volume><year>2016</year><fpage>695</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">27281742</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><source>Nat. Rev. Drug Discov.</source><volume>19</volume><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><mixed-citation publication-type="other" id="oref0020">World Health Organization: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en" id="intr0055">https://www.who.int/csr/sars/country/table2004_04_21/en</ext-link>/.</mixed-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="book" id="sbref0025"><person-group person-group-type="author"><name><surname>Knobler</surname><given-names>S.</given-names></name></person-group><chapter-title>Learning From SARS: Preparing for the Next Disease Outbreak: Workshop Summary</chapter-title><year>2004</year><publisher-name>National Academies Press</publisher-name><publisher-loc>Washington, DC</publisher-loc></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="book" id="sbref0030"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><chapter-title>Summary of the Global HIV Epidemic</chapter-title><year>2018</year><ext-link ext-link-type="uri" xlink:href="https://www.who.int/gho/hiv/en/" id="intr0060">https://www.who.int/gho/hiv/en/</ext-link></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>E.</given-names></name><name><surname>Enserink</surname><given-names>M.</given-names></name></person-group><source>Science</source><volume>303</volume><year>2004</year><fpage>944</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">14963300</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>P.</given-names></name><name><surname>Pannecouque</surname><given-names>C.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><source>J. Med. Chem.</source><volume>59</volume><year>2016</year><fpage>2849</fpage><lpage>2878</lpage><pub-id pub-id-type="pmid">26509831</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Ianevski</surname><given-names>A.</given-names></name><name><surname>Zusinaite</surname><given-names>E.</given-names></name><name><surname>Kuivanen</surname><given-names>S.</given-names></name><name><surname>Strand</surname><given-names>M.</given-names></name><name><surname>Lysvand</surname><given-names>H.</given-names></name><name><surname>Teppor</surname><given-names>M.</given-names></name><name><surname>Kakkola</surname><given-names>L.</given-names></name><name><surname>Paavilainen</surname><given-names>H.</given-names></name><name><surname>Laajala</surname><given-names>M.</given-names></name><name><surname>Kallio-Kokko</surname><given-names>H.</given-names></name></person-group><source>Antiviral Res.</source><volume>154</volume><year>2018</year><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">29698664</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A.B.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name></person-group><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1769</fpage><lpage>1770</lpage><pub-id pub-id-type="pmid">32208485</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Shao</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>N.</given-names></name><name><surname>Zuo</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><source>ACS Appl. Mater. Interfaces</source><volume>7</volume><year>2015</year><fpage>21571</fpage><lpage>21579</lpage><pub-id pub-id-type="pmid">26370151</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Elechiguerra</surname><given-names>J.L.</given-names></name><name><surname>Burt</surname><given-names>J.L.</given-names></name><name><surname>Morones</surname><given-names>J.R.</given-names></name><name><surname>Camacho-Bragado</surname><given-names>A.</given-names></name><name><surname>Yacaman</surname><given-names>M.J.</given-names></name></person-group><source>J. Nanobiotechnology</source><volume>3</volume><year>2005</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15661076</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Lara</surname><given-names>H.H.</given-names></name><name><surname>Ayala-Nu&#x000f1;ez</surname><given-names>N.V.</given-names></name><name><surname>Ixtepan-Turrent</surname><given-names>L.</given-names></name><name><surname>Rodriguez-Padilla</surname><given-names>C.</given-names></name></person-group><source>J. Nanobiotechnology</source><volume>8</volume><year>2010</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">20145735</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Hui</surname><given-names>C.</given-names></name><name><surname>Ho</surname><given-names>C.</given-names></name><name><surname>Luk</surname><given-names>J.</given-names></name><name><surname>Lau</surname><given-names>G.</given-names></name><name><surname>Che</surname><given-names>C.</given-names></name></person-group><source>Antivir. Ther.</source><volume>13</volume><year>2008</year><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">18505176</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>C.</given-names></name><name><surname>Tai</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Ling</surname><given-names>D.</given-names></name><name><surname>Gu</surname><given-names>F.</given-names></name><name><surname>Gan</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>F.</given-names></name><name><surname>Cai</surname><given-names>Q.</given-names></name></person-group><source>Cell Death Dis.</source><volume>10</volume><year>2019</year><fpage>392</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">31113937</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Sametband</surname><given-names>M.</given-names></name><name><surname>Kalt</surname><given-names>I.</given-names></name><name><surname>Gedanken</surname><given-names>A.</given-names></name><name><surname>Sarid</surname><given-names>R.</given-names></name></person-group><source>ACS Appl. Mater. Interfaces</source><volume>6</volume><year>2014</year><fpage>1228</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">24364493</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><source>Scientific Reports-UK</source><volume>6</volume><year>2016</year><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Cagno</surname><given-names>V.</given-names></name><name><surname>Andreozzi</surname><given-names>P.</given-names></name><name><surname>D&#x02019;Alicarnasso</surname><given-names>M.</given-names></name><name><surname>Silva</surname><given-names>P.J.</given-names></name><name><surname>Mueller</surname><given-names>M.</given-names></name><name><surname>Galloux</surname><given-names>M.</given-names></name><name><surname>Le Goffic</surname><given-names>R.</given-names></name><name><surname>Jones</surname><given-names>S.T.</given-names></name><name><surname>Vallino</surname><given-names>M.</given-names></name><name><surname>Hodek</surname><given-names>J.</given-names></name></person-group><source>Nat. Mater.</source><volume>17</volume><year>2018</year><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">29251725</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Lembo</surname><given-names>D.</given-names></name><name><surname>Donalisio</surname><given-names>M.</given-names></name><name><surname>Civra</surname><given-names>A.</given-names></name><name><surname>Argenziano</surname><given-names>M.</given-names></name><name><surname>Cavalli</surname><given-names>R.</given-names></name></person-group><source>Expert Opin. Drug Deliv.</source><volume>15</volume><year>2018</year><fpage>93</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">28749739</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Choudhary</surname><given-names>S.</given-names></name></person-group><source>Int. J. Drug Deliv.</source><volume>5</volume><year>2013</year><fpage>331</fpage><lpage>343</lpage></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C.W.</given-names></name><name><surname>Sam</surname><given-names>I.-C.</given-names></name><name><surname>Chong</surname><given-names>W.L.</given-names></name><name><surname>Lee</surname><given-names>V.S.</given-names></name><name><surname>Chan</surname><given-names>Y.F.</given-names></name></person-group><source>Antiviral Res.</source><volume>143</volume><year>2017</year><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">28457855</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Mastrangelo</surname><given-names>E.</given-names></name><name><surname>Mazzitelli</surname><given-names>S.</given-names></name><name><surname>Fabbri</surname><given-names>J.</given-names></name><name><surname>Rohayem</surname><given-names>J.</given-names></name><name><surname>Ruokolainen</surname><given-names>J.</given-names></name><name><surname>Nyk&#x000e4;nen</surname><given-names>A.</given-names></name><name><surname>Milani</surname><given-names>M.</given-names></name><name><surname>Pezzullo</surname><given-names>M.</given-names></name><name><surname>Nastruzzi</surname><given-names>C.</given-names></name><name><surname>Bolognesi</surname><given-names>M.</given-names></name></person-group><source>ChemMedChem</source><volume>9</volume><year>2014</year><fpage>933</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">24616282</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Gasc&#x000f3;n</surname><given-names>A.</given-names></name><name><surname>del Pozo-Rodr&#x000ed;guez</surname><given-names>A.</given-names></name><name><surname>Solin&#x000ed;s</surname><given-names>M.&#x000c1;.</given-names></name></person-group><source>Int. J. Nanomedicine</source><volume>9</volume><year>2014</year><fpage>1833</fpage><lpage>1843</lpage><pub-id pub-id-type="pmid">24748793</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Zholobak</surname><given-names>N.M.</given-names></name><name><surname>Mironenko</surname><given-names>A.P.</given-names></name><name><surname>Shcherbakov</surname><given-names>A.B.</given-names></name><name><surname>Shydlovska</surname><given-names>O.A.</given-names></name><name><surname>Spivak</surname><given-names>M.Y.</given-names></name><name><surname>Radchenko</surname><given-names>L.V.</given-names></name><name><surname>Marinin</surname><given-names>A.I.</given-names></name><name><surname>Ivanova</surname><given-names>O.S.</given-names></name><name><surname>Baranchikov</surname><given-names>A.E.</given-names></name><name><surname>Ivanov</surname><given-names>V.K.</given-names></name></person-group><source>Antiviral Res.</source><volume>127</volume><year>2016</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26769398</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Niikura</surname><given-names>K.</given-names></name><name><surname>Matsunaga</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>S.</given-names></name><name><surname>Yamaguchi</surname><given-names>H.</given-names></name><name><surname>Orba</surname><given-names>Y.</given-names></name><name><surname>Kawaguchi</surname><given-names>A.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Kajino</surname><given-names>K.</given-names></name><name><surname>Ninomiya</surname><given-names>T.</given-names></name></person-group><source>ACS Nano</source><volume>7</volume><year>2013</year><fpage>3926</fpage><lpage>3938</lpage><pub-id pub-id-type="pmid">23631767</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zeng</surname><given-names>S.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Kimura</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group><source>J. Med. Virol.</source><volume>86</volume><year>2014</year><fpage>886</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">24122866</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Draz</surname><given-names>M.S.</given-names></name><name><surname>Wang</surname><given-names>Yi.</given-names></name><name><surname>Chen</surname><given-names>F.F.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Shafiee</surname><given-names>H.</given-names></name></person-group><source>Adv. Funct. Mater.</source><volume>27</volume><year>2016</year><fpage>1604139</fpage><lpage>1604149</lpage><pub-id pub-id-type="pmid">29180949</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>A.M.</given-names></name><name><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><source>Chem. Soc. Rev.</source><volume>45</volume><year>2016</year><fpage>4074</fpage><lpage>4126</lpage><pub-id pub-id-type="pmid">27152673</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Guarner</surname><given-names>J.</given-names></name></person-group><source>Am. J. Clin. Pathol.</source><year>2020</year><fpage>1</fpage><lpage>2</lpage></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Coughlan</surname><given-names>L.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><source>Cell Host Microbe</source><volume>24</volume><year>2018</year><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">30001520</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><source>ACS Nano</source><volume>11</volume><year>2017</year><fpage>2637</fpage><lpage>2651</lpage><pub-id pub-id-type="pmid">28208020</pub-id></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="book" id="sbref0160"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><chapter-title>Chapter 7 - Two-dimensional nanoparticles for the delivery of anticancer drugs and cancer therapy</chapter-title><person-group person-group-type="editor"><name><surname>Parak</surname><given-names>W.J.</given-names></name><name><surname>Feliu</surname><given-names>N.</given-names></name></person-group><source>Frontiers of Nanoscience</source><year>2020</year><publisher-name>Elsevier</publisher-name><fpage>151</fpage><lpage>199</lpage></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>V.</given-names></name><name><surname>Papi</surname><given-names>M.</given-names></name></person-group><source>Nano Today</source><volume>33</volume><year>2020</year><object-id pub-id-type="publisher-id">100883</object-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>Y.K.</given-names></name><name><surname>Son</surname><given-names>S.</given-names></name><name><surname>Jang</surname><given-names>J.Y.</given-names></name><name><surname>Kwon</surname><given-names>M.H.</given-names></name><name><surname>Park</surname><given-names>K.D.</given-names></name></person-group><source>Pharm. Res.</source><volume>29</volume><year>2012</year><fpage>932</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">22139535</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>S.</given-names></name><name><surname>Onodera</surname><given-names>R.</given-names></name><name><surname>Inoue</surname><given-names>N.</given-names></name><name><surname>Takeuchi</surname><given-names>H.</given-names></name></person-group><source>Int. J. Pharm.</source><volume>543</volume><year>2018</year><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">29625169</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.S.</given-names></name><name><surname>Hung</surname><given-names>Y.C.</given-names></name><name><surname>Lin</surname><given-names>W.H.</given-names></name><name><surname>Huang</surname><given-names>G.S.</given-names></name></person-group><source>Nanotechnology</source><volume>21</volume><year>2010</year><object-id pub-id-type="publisher-id">195101</object-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Niikura</surname><given-names>K.</given-names></name><name><surname>Matsunaga</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>S.</given-names></name><name><surname>Yamaguchi</surname><given-names>H.</given-names></name><name><surname>Orba</surname><given-names>Y.</given-names></name><name><surname>Kawaguchi</surname><given-names>A.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Kajino</surname><given-names>K.</given-names></name><name><surname>Ninomiya</surname><given-names>T.</given-names></name><name><surname>Ijiro</surname><given-names>K.</given-names></name><name><surname>Sawa</surname><given-names>H.</given-names></name></person-group><source>ACS Nano</source><volume>7</volume><year>2013</year><fpage>3926</fpage><lpage>3938</lpage><pub-id pub-id-type="pmid">23631767</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Quach</surname><given-names>Q.H.</given-names></name><name><surname>Ang</surname><given-names>S.K.</given-names></name><name><surname>Chu</surname><given-names>J.H.J.</given-names></name><name><surname>Kah</surname><given-names>J.C.Y.</given-names></name></person-group><source>Acta Biomater.</source><volume>78</volume><year>2018</year><fpage>224</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">30099200</pub-id></element-citation></ref></ref-list><bio><graphic xlink:href="fx2_lrg"/><p><bold>Yongjiu Chen</bold> is currently a Ph.D. student under the supervision of Professor Sijin Liu in the State Key Laboratory of Environmental Chemistry and Ecotoxicology, the Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences (CAS). He has received his B.S. degree from Shandong University in 2015. His research interests include the translational toxicology of ENMs.</p></bio><bio><graphic xlink:href="fx3_lrg"/><p><bold>Juan Ma</bold> is currently an associate professor at the State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences (CAS). She has received her bachelor&#x02019;s degree in 2011 from South China University of Technology and Ph.D. in 2015 from the University of Chinese Academy of Sciences. Her research focuses on the immune toxicities of pollutants and the underlying mechanisms, especially the adverse outcomes caused by nanomaterials and airborne fine particles.</p></bio><bio><graphic xlink:href="fx4_lrg"/><p><bold>Ming Xu</bold> has obtained his B.S. and Ph.D. degrees from Xiamen University in 2006 and 2011. He was a postdoctoral fellow in Prof. Ryszard Lobinski&#x02019;s group at the Centre National de la Recherche Scientifique (CNRS) from 2011 to 2013. He joined the Research Center for Eco-Environmental Sciences (RCEES), Chinese Academy of Sciences (CAS), in 2014, and became an associate professor in 2016. His research interests include the health risks and toxicological mechanisms of heavy metals and nanoparticles. He was awarded the &#x0201c;National Science Fund for Excellent Young Scholars&#x0201d; by the National Natural Science Foundation of China (NSFC) in 2019. He has also been a member of the &#x0201c;Youth Innovation Promotion Association&#x0201d; of CAS since 2018.</p></bio><bio><graphic xlink:href="fx5_lrg"/><p><bold>Sijin Liu</bold> is currently a professor at the State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences (CAS). His research interests include: (i) Environmental behaviors, biological effects, and health risks of engineered nanomaterials and fine air particles. (ii) The molecular mechanisms responsible for environmental pollutant-induced oncogenic effects and disordered element metabolism. Dr. Liu is a recipient of the &#x0201c;Outstanding Young Scientist&#x0201d; award from the National Natural Science Foundation of China (NSFC). He had served as the Chief Scientist for the project of Environmental Behaviors and Toxicity of Engineered Nanomaterials under the &#x0201c;National Basic Research Program of China (973 Program)&#x0201d; from 2014 to 2018.</p></bio></back></article>